Patents by Inventor Pia Norregaard

Pia Norregaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240209054
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: September 22, 2023
    Publication date: June 27, 2024
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
  • Patent number: 11814417
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: November 14, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20220041676
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: April 2, 2021
    Publication date: February 10, 2022
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
  • Patent number: 11008375
    Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
  • Patent number: 11001619
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 11, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20190256569
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 22, 2019
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20190218270
    Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: August 27, 2018
    Publication date: July 18, 2019
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Jacob Ulrik FOG, Carsten Boye KNUDSEN
  • Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Patent number: 10253078
    Abstract: The present invention relates to acylated GIP analogs which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Publication number: 20190055296
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 18, 2018
    Publication date: February 21, 2019
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Patent number: 10093713
    Abstract: The present invention relates to acylated GIP analogs which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
  • Patent number: 9975939
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Publication number: 20170240609
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 24, 2017
    Applicant: Zealand Pharma A/S
    Inventors: Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
  • Publication number: 20160280754
    Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 29, 2016
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Jacob Ulrik FOG, Carsten Boye KNUDSEN
  • Publication number: 20160009777
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Patent number: 9180169
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Publication number: 20140080757
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 20, 2014
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Jakob Lind TOLBORG, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas
  • Publication number: 20060235035
    Abstract: Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is selected from hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, —CHO, nitrile, alkyl, alkenyl or alkynyl groups, —SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as —CH2CF3, —CF2CF3, —CF3, —OCF3, —SCF3; —SO2NH2, —SO2NHAlk, —SO2NAlk2, —SO2Alk; X is H, F, Cl, Br, I, —SCH3, —CF3, —OCF3, —SCF3, OCH3, or lower alkyl or alkenyl group; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocyclyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups, arylalkoxy
    Type: Application
    Filed: April 8, 2003
    Publication date: October 19, 2006
    Applicant: 7TM Pharma A/S
    Inventors: Thomas Hogberg, Emelie Bjurling, Jean-Marie Receveur, Trond Ulven, Paul Little, Christian Elling, Pia Norregaard
  • Publication number: 20060111357
    Abstract: The present invention relates to the use of quinoline compounds for the preparation of a pharmaceutical and/or a cosmetic composition for the treatment, prophylaxis and/or diagnosis of a condition caused by or involving a melanin-concentrating hormone. The invention also relates to novel quinoline compounds per se. The quinoline compounds have been found to interact with a melanin-concentrating hormone receptor, a MCH receptor. The compounds have modulating activity on the MCH receptor such as e.g. antagonistic, agonistic or allosteric activity and are useful for medicinal or cosmetic purposes such as, e.g. in the treatment or prevention of feeding disorders like obesity, metabolic syndrome, Type II diabetes, bulimia, etc. or in the treatment or prevention of depression.
    Type: Application
    Filed: December 11, 2003
    Publication date: May 25, 2006
    Inventors: Thomas Frimurer, Trond Ulven, Thomas Hogberg, Pia Norregaard, Paul Little, Jean-Marie Receveur